Annual report pursuant to Section 13 and 15(d)

Apexian Sublicense Agreement (Details)

v3.20.4
Apexian Sublicense Agreement (Details) - USD ($)
$ in Thousands
 12 Months Ended
Nov. 05, 2020
Dec. 31, 2020
Dec. 31, 2019
Sublicense Agreement [Abstract]      
Common stock issued (in shares) 7,091,878    
Program costs   $ 1,769 $ 0
Apexian Sublicense Agreement [Member]      
Sublicense Agreement [Abstract]      
Common stock issued (in shares)   843,751  
Payment for license agreement   $ 2,100  
Program costs   400  
Apexian Sublicense Agreement [Member] | Development and Regulatory Milestones [Member] | Maximum [Member]      
Sublicense Agreement [Abstract]      
Milestone payments   11,000  
Apexian Sublicense Agreement [Member] | Sales Milestones [Member] | Maximum [Member]      
Sublicense Agreement [Abstract]      
Milestone payments   20,000  
Ref-1 Inhibitor Program [Member]      
Sublicense Agreement [Abstract]      
Program costs   $ 300